Medical Facilities Corporation (TSX: DR) - Deep Dive Research Report

1. What the Company Does

Medical Facilities Corporation (MFC) is a Canadian holding company that owns controlling interests in specialty surgical hospitals in the United States. It does not operate emergency rooms, intensive care units, psychiatric wards, or general medicine floors. Its hospitals exist for one purpose: performing scheduled, non-emergency surgical procedures - primarily orthopedic surgery, spine surgery, and pain management - in a focused environment built around clinical excellence and physician ownership.

The business model is straightforward. Physicians who perform high volumes of complex elective surgery need access to operating rooms, specialized nursing staff, anesthesia support, surgical instruments calibrated for specific procedures, imaging equipment, and recovery beds. MFC provides all of that infrastructure. When a patient's commercial insurer or Medicare pays the hospital bill, the payment splits between the surgeon's professional fee (billed separately by the physician) and MFC's facility fee. MFC captures that facility fee - recording it as revenue - and pays for running the physical plant: nursing staff, drugs and surgical supplies, administrative overhead, and depreciation. The remainder flows to MFC's 51% ownership share and to the physician co-owners who hold 49%.

The physician-ownership structure is central to understanding why these hospitals function differently from the facilities they compete against. MFC's hospitals were founded by surgeons who wanted to practice in facilities they controlled. MFC's corporate role is to provide capital, management systems, and financial infrastructure without disrupting that clinical ownership. Physicians with equity stakes are among the hardest-working, highest-volume operators in any medical market: their equity is worth more when the hospital performs well, so they are motivated to recruit talented colleagues, maintain quality, and drive case volumes. A general hospital where surgeons are employees cannot easily replicate this alignment.

"Nearly all of its revenue is generated from the facility fee charged to the patient, or their insurer, for access to infrastructure, equipment, nursing staff, and support services." - MFC company overview

Founded in 2004 as a British Columbia corporation, MFC completed its IPO the same year, acquiring controlling interests in three specialty surgical hospitals. It operated for years as an income trust vehicle distributing hospital cash flows to Canadian unitholders, then converted to a corporation structure, accumulated a portfolio of specialty hospitals and ambulatory surgery centers, and by 2022 had six facilities.

In September 2022, the board and management made a decisive pivot. Rather than continuing to acquire facilities, MFC announced it would divest non-core assets and return capital to shareholders. This was not a gentle strategic realignment - it was a full reversal. Between 2023 and early 2026, MFC sold its entire ambulatory surgery center portfolio, its interest in Black Hills Surgical Hospital (sold November 2024 to Sanford Health at a valuation implying roughly 9x EBITDA), its interest in Oklahoma Spine Hospital (sold January 2026 to SSM Health for US$46 million), and its interest in The Surgery Center of Newport Coast (sold December 2025 for US$1.5 million).

What remains is a two-hospital platform: Arkansas Surgical Hospital in North Little Rock, Arkansas, and Sioux Falls Specialty Hospital in Sioux Falls, South Dakota. Both are 51% owned by MFC. Both are among the top-ranked specialty surgical facilities in their respective markets. Both have been operating for decades, are fully staffed, and generate consistent cash flows from procedures that the aging US population increasingly requires.

This is now a company in its capital-return phase, not its growth phase. The question an investor faces is concrete: can management deploy the substantial cash accumulated from divestitures intelligently, or will it sit idle while the two hospitals sustain themselves organically?

2. Business Segments

Sioux Falls Specialty Hospital (SFSH) - Sioux Falls, South Dakota

Sioux Falls Specialty Hospital has been operating since 1985 - two decades before MFC even existed. MFC acquired a 51% controlling interest in 2004 at the time of its IPO. The hospital sits adjacent to the Avera McKennan Hospital campus in Sioux Falls, at 910 East 20th Street, in what is the largest city in South Dakota.

The numbers that define SFSH's market position are striking: approximately 45% of all surgeries in South Dakota are performed at this one facility. For a single specialty hospital in a state of 900,000 people, that level of market share is the result of four decades of physician relationships, geographic concentration, and clinical reputation built before any competitor could establish a comparable foothold. South Dakota is rural - surgeons and patients travel from across the state to Sioux Falls - and SFSH is the destination.

The facility spans 76,000 square feet and operates 15 operating rooms. Primary specialties are orthopedics, pain management, gastroenterology and urology, and ear, nose and throat surgery. SFSH also operates urgent care and primary care clinics, along with occupational health services - revenue streams that extend the hospital's community footprint beyond elective surgery. Diagnostic capabilities include high-field 3T MRI and open upright MRI, premium imaging tools that serve surgical referral pathways.

SFSH received the Blue Distinction Center+ designation from Wellmark Blue Cross and Blue Shield for both knee and hip replacement and spine surgery. This designation requires meeting specific quality and outcomes thresholds and is used by insurers to direct high-acuity patients toward preferred providers. It functions as both a quality signal and a contractual advantage: Blue Distinction status channels Wellmark-insured patients toward SFSH when they need a joint replacement in South Dakota.

The Q2 2025 earnings call revealed the operational vulnerability hiding inside SFSH's market dominance: when a key physician group relocated their clinic, revenue at Sioux Falls declined materially in a single quarter. The referral relationship between an orthopedic practice and a hospital can break if the logistical connection changes, even without the physician departing permanently. The clinic relocation disrupted case routing, and volume dropped. By Q3 2025, management confirmed recovery as the referral relationship normalized.

In the portfolio's operating income split (following all divestitures), SFSH contributes approximately 55% of MFC's remaining two-hospital operating income.

Arkansas Surgical Hospital (ASH) - North Little Rock, Arkansas

Arkansas Surgical Hospital opened in 2005, founded by orthopedic and spine surgeons in central Arkansas who wanted a physician-controlled environment for complex elective surgery. MFC acquired a 51% controlling interest in ASH in 2012, seven years after the hospital's founding. The physician-owners retained 49%, with 5% of that physician stake structured as exchangeable for MFC common shares - a provision that further aligns physician interests with the corporate parent at the holding company level.

The physical plant reflects the founders' ambitions: 126,000 square feet, 13 operating rooms, and 41 private patient suites. The "hotel-like" environment that ASH markets is not branding - the facility was designed from inception to prioritize patient experience in a way that general hospitals, built to handle trauma and emergency medicine, typically cannot match. The result is consistent top-ranking: ASH received the Human Experience Guardian of Excellence Award for the sixth consecutive year as of 2025, placing it in the top 5% of US hospitals nationwide for patient experience. AY Magazine readers voted it the Best Doctor-Owned Hospital in Arkansas.

The clinical programme at ASH is led by orthopedics and spine surgery. Additional service lines include breast oncology, reconstructive surgeries, pain management, and diagnostic imaging (CT, MRI, and myelography). The breadth matters operationally: a surgeon's patient who needs pre-operative imaging, the surgical procedure itself, and post-operative pain management can have all three provided within a single facility, increasing case throughput and ancillary revenue capture.

The pain management service line has been a persistent headwind through 2025 and into 2026. Physician departures reduced pain management case volumes by more than 15% in Q3 2025, and volumes continued declining through Q1 2026. Management disclosed on the Q2 2025 call that they recruited a new pain doctor (immediate start) and a new spine surgeon (September 2025 start). The spine surgical volumes have shown improvement, but the pain management volume has not stabilized - four consecutive quarters after the issue was first disclosed, pain management cases are still falling. This is the unresolved operational risk within the ASH segment.

ASH contributes approximately 45% of MFC's remaining two-hospital operating income.

Segment Summary Table

3. Products and Business Detail

The Revenue Architecture

MFC's revenue is almost entirely facility fee revenue. When a surgeon performs a knee replacement at ASH or a spine fusion at SFSH, the hospital charges a facility fee to the patient's insurer or directly to Medicare. That fee covers:

• Use of the operating room, including sterilized surgical instruments specific to the procedure
• Nursing staff across the care continuum: pre-operative preparation, intraoperative scrub and circulating nursing, and post-anesthesia care
• Anesthesia services coordination (anesthesiologists bill their professional fee separately)
• Surgical implants and medical supplies - a material cost item: drugs and supplies rose more than 10% in Q3 2025 as higher-acuity cases requiring more expensive orthopedic implants grew
• Diagnostic imaging if performed at the facility before or after surgery
• Recovery bay time and post-operative nursing until discharge

The payer mix is approximately 40% Medicare/Medicaid and 55% commercial (private insurance), with 5% other. This is meaningfully more favorable than typical general hospital payer mixes. Specialty surgical hospitals historically attracted commercially insured patients because their streamlined environment, shorter wait times, and patient experience scores draw healthier, elective-surgery patients - the same population that carries commercial insurance at higher rates.

Revenue per case is driven by three variables: procedure complexity and case mix (spine surgery carries higher facility fees than a pain injection), payer mix (commercial rates are structurally higher than Medicare), and volume (cases completed per OR per day). Favorable movement in any of these drives revenue growth; unfavorable shifts create headwinds, as MFC experienced in Q2 2025 at Sioux Falls.

Procedure Catalogue

Orthopedics and Spine - The core of both hospitals and the source of the highest per-case facility fees. Total joint replacements (hip, knee, and shoulder), arthroscopic procedures, and spine surgery (fusions, decompressions, disc replacements) generate the highest economics and are the primary volume driver. Both hospitals hold specific quality designations in this clinical category.

Pain Management - Injections, nerve blocks, radiofrequency ablation, and other non-surgical pain procedures. Lower facility fee per case than surgery, but high-volume procedures that fill operating schedules and recovery capacity between surgical cases. This line has been under pressure at ASH due to physician departures: cases declined more than 15% in Q3 2025 and more than 20% in Q1 2026. SFSH also showed pain management softness in Q4 2025.

Imaging - Diagnostic CT, MRI (including high-field 3T and open upright at SFSH), and myelography. These services generate ancillary revenue from surgical patients requiring pre-operative imaging and post-operative follow-up scans. SFSH's 3T MRI is a premium capability that supports high-acuity neurological and orthopedic imaging.

Urgent and Primary Care - SFSH operates urgent care locations positioned as a faster and more cost-effective alternative to emergency rooms. These clinics generate independent volume and serve as community touchpoints that may convert into elective surgical referrals.

Occupational Health - SFSH's WorkForce program serves employers in the Sioux Falls area with injury assessment, occupational health management, and disability management. This is a recurring volume business tied to local employer contracts.

Breast Oncology and Reconstructive Surgery - An ASH-specific differentiation. This positions ASH as more than an orthopedic and spine specialist, allowing it to draw from surgical oncology referral networks in central Arkansas.

Physician Partnership Mechanics

The governance of each hospital operates under a joint venture structure. MFC holds its 51% through a wholly-owned subsidiary; the physician-owners collectively hold 49%. Clinical operations are managed with significant physician input - the co-ownership structure gives physician-owners a direct voice in decisions about equipment, staffing, scheduling, and strategic direction.

New physicians joining the medical staff can acquire an ownership stake in the hospital. Arkansas Surgical Hospital has publicly announced multiple new physician-owner additions in recent years. This expansion of the physician-owner base is operationally significant: a physician with equity is more loyal, more motivated to drive volume, and more likely to recommend the facility to talented colleagues they want to recruit.

The financial flow works like this: MFC consolidates 100% of each hospital's revenues and expenses on its financial statements. The physicians' 49% economic interest is reported as non-controlling interest - it appears in the income statement as a charge against consolidated net income before MFC's 51% share is available to common shareholders.

Geographic Footprint and FX

Both hospitals serve regional catchment areas larger than their immediate cities. Sioux Falls draws patients from across South Dakota and neighboring states given SFSH's dominant position. North Little Rock draws from central Arkansas and regional referrals statewide.

MFC is headquartered in Toronto, Ontario - a Canadian holding company, TSX-listed, with essentially all operating assets in the United States. Revenues are earned in US dollars, while the company declares dividends in Canadian dollars. This creates a structural FX exposure: when the Canadian dollar strengthens, the CAD value of US hospital earnings contracts without any operational change.

4. Customers

Payers: The Economic Buyers

In the US healthcare system, the entity that writes the check for a hospital's services is typically the insurer or a government program, not the patient. MFC's hospitals contract with:

Commercial Insurance Companies (approximately 55% of revenue): Blue Cross Blue Shield plans - specifically Wellmark Blue Cross and Blue Shield, which accredits SFSH with Blue Distinction Center+ for knee, hip, and spine procedures - along with major national carriers. Commercial rates are negotiated in multi-year contracts. SFSH's Blue Distinction designation creates a specific contractual advantage: Wellmark actively directs its members toward Blue Distinction facilities for covered procedures, channeling patients toward SFSH and giving the hospital leverage in rate negotiations. A Blue Distinction+ hospital can negotiate from a position of demonstrated quality; a facility without the designation cannot.

Medicare (the largest single government payer): Approximately 40% of volume (combined with Medicaid). Medicare patients are predominantly elderly orthopedic surgery candidates - joint replacements, spine surgeries, and pain management for degenerative conditions. This is the demographic core of both hospitals' volume base. The 2026 CMS final rule increased OPPS and ASC payment rates by 2.6%, a modest tailwind to Medicare reimbursement.

Medicaid: Per the Q2 2025 concall, CFO David Watson stated clearly: "Medicaid really represents an immaterial portion of our business." This matters because site neutrality and Medicaid reimbursement discussions generate significant regulatory headlines - but MFC's direct exposure is limited. Medicaid patients typically cannot access physician-owned specialty hospitals at high rates because these hospitals do not maintain the full emergency-care infrastructure that state Medicaid contracts often require.

Physicians: The Volume Source

The actual decision-maker for where a patient receives elective surgery is the referring surgeon. A patient who needs a hip replacement goes where their orthopedic surgeon operates. Physician co-owners at MFC's hospitals are effectively a captive referral base: their equity interest creates a strong economic and logistical incentive to direct their patients to the hospital where they have ownership and where they operate regularly.

Physician loyalty is the deepest switching cost in MFC's business model. An orthopedic surgeon who owns a 2% equity stake in Arkansas Surgical Hospital has strong economic and professional reasons to operate primarily at ASH. The Q2 2025 Sioux Falls disruption - where a physician group's clinic relocation changed referral logistics even without the physicians leaving - illustrates what happens when that loyalty is disrupted logistically. A full physician departure is more damaging: it removes both the volume and the referral pipeline simultaneously.

Patients: Quality-Driven Selection

Individual patients choose a specialty hospital based largely on their physician's recommendation. But they increasingly also research quality ratings, patient experience scores, and facility reputation independently. ASH's Human Experience Guardian of Excellence Award - top 5% of US hospitals for patient experience for six consecutive years - is a direct marketing advantage in this environment. Patients comparing facilities on CMS's Hospital Compare platform see quantified quality metrics that differentiate ASH from a large general hospital.

The focused care environment at both ASH and SFSH - private patient suites, specialized nursing teams, shorter wait times, coordinated logistics, hotel-like aesthetics - represents a genuine product differentiation relative to general hospitals where surgical patients coexist with emergency medicine and acute illness cases.

Switching Costs

For physician-owners, switching costs are high. Unwinding an equity position in a private hospital is complex; a surgeon who has built their practice around a specific OR schedule, nursing team, and equipment configuration has strong path-dependency with that facility.

For commercial insurers, the contracted relationship creates medium-term switching costs. Multi-year contracts and network designation processes make rapid changes difficult.

For patients, switching costs are largely delegated to the physician. If the physician stays, the patient follows.

5. Competitive Landscape

National Roll-Up Chains: Scale Without Local Depth

The US ambulatory/specialty surgical market is dominated by large national platforms with procurement scale, insurance contracting leverage, and physician recruiting brand advantages that MFC cannot match:

USPI (Tenet Healthcare): The largest operator as of year-end 2024 with approximately 520 ASCs and 25 surgical hospitals across 37 states. USPI can negotiate blanket contracts with national insurers and purchase surgical implants at volume discounts unavailable to a two-hospital operator.

SCA Health (Optum/UnitedHealth Group): Approximately 423 ASCs backed by the largest US health insurer. SCA Health benefits from UnitedHealth's in-network relationships and the strategic capacity to direct UHC-insured patients toward SCA facilities - a profound structural advantage.

Amsurg (Envision Healthcare): Approximately 250 ASCs.

HCA Healthcare: 124 ASCs integrated into a broader network of more than 2,000 care sites.

Surgery Partners: A growing physician-aligned platform with structural similarities to MFC's co-ownership model.

National Surgical Hospitals: 23 specialty hospitals operating under a physician-partnership structure directly comparable to MFC's approach.

Regent Surgical Health: Specializes in acquiring and repositioning underperforming physician-owned specialty hospitals.

Why MFC's Hospitals Are Different

MFC's hospitals compete in local markets, not national ones. At SFSH, the primary competitors are Avera Health (whose main campus is literally adjacent) and other hospital systems in Sioux Falls. At ASH, competitors are CHI St. Vincent, Baptist Health, and UAMS Medical Center in the Little Rock area. The national chains' presence in these specific markets is limited.

The decisive structural advantage is regulatory: the 2010 Affordable Care Act prohibited any new physician-owned hospital from receiving Medicare or Medicaid payments. Existing hospitals were grandfathered, and the prohibition on new entrants is permanent unless Congress acts. Any potential new physician-owned surgical hospital in Sioux Falls or North Little Rock cannot receive Medicare payments - making it economically unviable as a standalone specialty hospital. MFC's existing facilities are, in effect, protected from direct like-for-like competition in their local markets. There are only approximately 250 specialty surgical hospitals in the entire US; no new ones can be created.

Grandfathered status also comes with restrictions: existing physician-owned hospitals cannot expand capacity (beds or ORs) without meeting strict CMS criteria. This limits growth optionality but does not prevent existing capacity from being used more efficiently.

Head-to-Head Competitive Position

On quality: MFC's hospitals win. Top 5% nationally for patient experience (ASH), Blue Distinction Center+ for knee, hip, and spine (SFSH), consistent award recognition that general hospital systems rarely achieve in elective surgical specialties.

On pricing power with commercial insurers: MFC holds meaningful leverage because its quality designations give insurers a reason to create preferred network relationships, and because the lack of competing physician-owned alternatives in these local markets limits insurer alternatives.

On scale and procurement: MFC loses to USPI, SCA Health, and Amsurg on every dimension of scale. A two-hospital company cannot negotiate implant discounts comparable to a 500+ facility platform.

On physician alignment: MFC's co-ownership model creates the strongest physician loyalty structure possible. The Affordable Care Act has made this structure effectively irreplaceable.

On growth optionality: Constrained by ACA expansion restrictions and by management's stated strategy of capital return over acquisition.

Barriers to Entry

The regulatory barrier is absolute: new physician-owned hospitals cannot be built and receive Medicare payments. This has been true since 2010 and has survived multiple healthcare reform cycles without change. Any new competitor in MFC's local markets must build a full general hospital - a far more capital-intensive undertaking with different economics - or acquire an existing facility.

Secondary barriers include physician relationships (decades of cultivated OR loyalty), quality reputation (top-5% nationally takes years of sustained performance to achieve), and local market infrastructure (the logistical integration between physician clinics and their preferred operating facility).

6. Industry

Demand Drivers

Demographics: The US population aged 65 and over will reach peak concentration over the coming decade as baby boomers move through their 70s and 80s. Joint replacement (hip and knee), spine surgery, and pain management procedures are predominantly a need of the elderly. This demographic tailwind is structural, durable, and does not depend on economic cycles. The Centers for Medicare & Medicaid Services project procedure volume at ambulatory surgical facilities to grow approximately 21% over the 2025-2035 period.

Procedure migration from general hospitals to outpatient and specialty settings: CMS policy has progressively expanded the list of procedures eligible for ambulatory reimbursement. The 2026 CMS final rule adds 547 procedures to the ASC-covered procedures list and begins a phased elimination of the inpatient-only list (removing 285 musculoskeletal procedures in 2026 alone). This migration benefits specialty surgical facilities because procedures that previously required a hospital admission can now be performed in an outpatient or short-stay setting, broadening the addressable volume for facilities like MFC's.

Payer incentives for cost reduction: Commercial insurers and Medicare are actively steering patients toward lower-cost ambulatory settings. Specialty surgical hospitals carry lower overhead than full-service general hospitals (no emergency department, no ICU, no psychiatric unit), allowing them to perform many procedures at equivalent or better quality with lower total cost. Payers benefit economically from this migration, which drives negotiation and in-network designation decisions.

Minimally invasive surgical technology: Robotic surgical systems and minimally invasive techniques have expanded what can be safely performed in ambulatory or short-stay settings. A procedure requiring a three-day hospital stay a decade ago may now be same-day or one-night. This technology tailwind structurally expands the addressable market for specialty hospitals.

Industry Size

The US ambulatory surgical center market is estimated at approximately $46 billion to $84 billion depending on the scope definition used. Market growth projections range from a 4.1% to 5.6% CAGR through 2030-2032. There are approximately 6,500 Medicare-certified ASCs nationwide; specialty surgical hospitals represent a far smaller subset of approximately 250 facilities nationally - a scarcity that reflects both regulatory restrictions and capital requirements.

Regulatory Environment

ACA Physician-Owned Hospital Restrictions (2010): Existing physician-owned hospitals were grandfathered and can continue receiving Medicare/Medicaid payments. No new physician-owned hospitals can qualify. This is the single most important regulatory fact for understanding MFC's competitive position.

Site Neutrality: An ongoing CMS policy direction aimed at equalizing payment rates between on-campus hospital outpatient departments, off-campus HOPDs, and freestanding settings like ASCs and specialty hospitals. For MFC's freestanding facilities, site neutrality is two-directional: if off-campus hospital outpatient departments face payment reductions (as they do under the 2026 CMS rule, which cuts off-campus HOPD payments for drug administration to 40% of the OPPS rate), some procedures and physician referral flows may migrate toward freestanding settings, creating a tailwind for MFC. A broader site neutrality rule that reduces specialty hospital reimbursement directly would be adverse. CFO Watson noted on the Q2 2025 call that reimbursement changes are not expected before 2027 or early 2028.

CMS 2026 Final Rule: 2.6% payment rate increase for OPPS and ASC settings. Addition of 547 procedures to the ASC-covered procedures list. Phased elimination of the inpatient-only list beginning with 285 musculoskeletal procedures in 2026. Net positive for the specialty surgical segment.

No Surprises Act and Price Transparency: MFC's facilities comply with both requirements. This is baseline regulatory compliance in the current environment, not a differentiated strategic advantage.

Cyclicality

The specialty surgical hospital sector is moderately defensive. Elective surgery is deferrable during economic downturns - patients may postpone a knee replacement if they lose their job or face insurance disruption - which creates some cyclicality. However, the demographic driver creates a rebound effect: deferred procedures do not disappear, they accumulate. Medicare patients, who represent a substantial portion of MFC's volume, have limited financial ability to defer medically necessary procedures. The sector is less cyclical than capital goods or retail, but more cyclical than essential pharmaceuticals.

Healthcare labor markets add a cyclical dimension from the cost side: during economic expansions, nursing and clinical staff wages are drawn higher by competition from other industries. During contractions, labor markets soften, reducing wage pressure. MFC's salaries and benefits line increased more than 6% in Q3 2025 - a reflection of ongoing healthcare labor market tightness in both South Dakota and Arkansas.

7. Growth Triggers

• Recruitment of a new pain management physician at Arkansas Surgical Hospital, with an immediate start date, and a new spine surgeon with a September 2025 start. Management disclosed these specific hires to address the pain case volume decline that began in Q2 2025. The spine surgeon addition is intended to reinforce the orthopedic/spine core; the pain doctor is targeted at reversing the double-digit case decline in pain management. (Q2 2025 concall, August 7, 2025)

"We look forward to Sioux Falls' return to more normalized operations in the back half of the year." - CEO Jason Redman, Q2 2025 concall

• Sioux Falls Specialty Hospital's recovery following the resolution of a key referral physician group's clinic relocation. Management identified the disruption as logistical rather than clinical, and guided for normalization in H2 2025. This trigger was confirmed delivered when Q3 2025 revenues rose materially across continuing operations. (Q2 2025 concall, August 7, 2025; confirmed Q3 2025 concall, November 6, 2025)

• New C$40 million revolving credit facility with CIBC, completed in Q3 2025, with a C$25 million expansion option available. This replaced an expiring facility from National Bank and provides MFC with financial flexibility to pursue opportunistic capital deployment without immediately drawing on its cash reserves. The expansion option signals that the bank is comfortable extending additional credit if needed. (Q3 2025 concall, November 6, 2025)

• Evaluation of capital return alternatives following the completion of the Oklahoma Spine Hospital divestiture and receipt of US$46 million in gross proceeds. Management stated they are evaluating share repurchases (NCIB or another Substantial Issuer Bid), distributions, or other shareholder return mechanisms. With no corporate debt and a substantial consolidated cash position as of Q1 2026, this capital deployment decision is the most material near-term trigger for per-share economics. (Q4 2025 concall, March 12, 2026; Q1 2026 concall, May 7, 2026)

• Favorable payer mix and elevated orthopedic/spine procedure volumes at both hospitals continuing into 2026. Revenue from continuing operations grew at an accelerating rate in Q1 2026, with management attributing growth to favorable commercial payer mix and higher-acuity orthopedic and spine case selection - a clinical mix improvement that translates directly into higher per-case facility fees. (Q1 2026 concall, May 7, 2026)

• Arkansas Surgical Hospital's capacity headroom: 13 operating rooms with capacity to absorb volume growth without capital expansion. Management has consistently referenced available OR capacity as a constraint-free growth lever - additional surgical cases at either hospital flow through to operating income without requiring incremental capital expenditure on plant or equipment. (Multiple concalls)

8. Key Risks

1. Physician Departure and Volume Concentration Risk

This is the most material near-term risk, and the one that has already damaged results. MFC's hospitals generate revenue from a relatively small number of high-volume surgeons. When a physician departs or a referral relationship breaks, the financial impact is immediate: pain management cases at Arkansas Surgical Hospital declined more than 20% in Q1 2026, more than a year after the initial disruption began. A departure from the orthopedic or spine programme - which carries the highest per-case facility fees - would be substantially more damaging than the pain management decline.

The mechanism is direct: a spine surgeon performing eight fusions per month generates several hundred thousand dollars in monthly facility fees for MFC. If that surgeon retires, relocates, or shifts their primary hospital affiliation, MFC's revenue declines with no corresponding reduction in fixed costs (nursing staff, OR overhead, administrative expense). Recruiting a replacement takes six to twelve months. The replacement then requires another twelve to twenty-four months to ramp to full volume. The total revenue gap from a single senior surgeon's departure can span two to three years.

Given MFC's concentration in two hospitals, there is no portfolio cushion. A physician problem at either facility flows directly and immediately through to consolidated results.

2. Regulatory Risk - ACA Grandfathered Status Restrictions

MFC's hospitals operate under the ACA's "whole hospital" exception for physician-owned facilities. Grandfathered status allows physician-owners to self-refer Medicare patients. However, it also prohibits capacity expansion - the hospitals cannot add beds or operating rooms without CMS approval under strict criteria. This constrains organic growth: when surgical volumes at a facility approach OR capacity, MFC cannot simply build a new OR.

The deeper risk is legislative: if Congress narrows or eliminates the grandfathering provision in a future healthcare reform bill, MFC's physician-ownership model could become legally non-compliant or economically unviable at current payer mix levels. This is a low-probability but potentially company-altering risk that is difficult to hedge.

3. Site Neutrality Legislation

The mechanism: if CMS or Congress implements broad site neutrality rules that reduce the reimbursement premium for freestanding specialty hospitals relative to other care settings, MFC's per-case facility fee revenue would contract without any operational change. The Q2 2025 concall CFO commentary placed this risk timeline at "not before 2027 or early 2028," and the 2026 CMS final rule actually expanded ASC reimbursement and covered procedures. But the direction of policy is toward equalization, and specialty hospitals' current reimbursement premium over general hospital outpatient settings is a target.

"Medicaid really represents an immaterial portion of our business" and reimbursement changes are not expected before 2027 or early 2028. - CFO David Watson, Q2 2025 concall

This was reassuring in Q2 2025. The legislative timeline is, however, inherently uncertain.

4. Healthcare Wage and Supply Inflation

Healthcare is a labor-intensive industry in a structurally tight labor market. Nursing and clinical support staff wages at specialty hospitals compete with general hospitals, travel nursing firms, and non-healthcare employers for the same workforce. Salaries and benefits increased more than 6% in Q3 2025. Drugs and surgical supplies - particularly high-cost orthopedic and spine implants - increased more than 10% in the same quarter as higher-acuity procedures required more expensive hardware.

If wage and supply cost inflation structurally outpaces CMS reimbursement rate increases (which grow at 2-3% annually) and commercial rate increases (typically negotiated every two to three years), the margin spread contracts without any change in volume.

Management has referenced a standardized implant formulary initiative as a potential cost reduction measure - systematically standardizing which implant brands are used for specific procedures to capture volume-based discounts. This requires physician cooperation since surgeons have established preferences for specific implant brands they have trained with.

5. Two-Facility Concentration and Strategic Drift

Having divested four of six original facilities, MFC is as concentrated as it can be: two hospitals, each 51% owned. One sustained operational problem - a physician departure, a regulatory change specific to a state, a natural disaster, a reputational incident - affects the entire business.

There is also a strategic coherence question: what does MFC do with its substantial cash position? If management cannot identify acquisitions at acceptable multiples or execute another major buyback, the company faces a slow erosion of strategic relevance. A business returning capital faster than it is generating new operating assets eventually becomes smaller in absolute terms. The two hospitals are operationally stable, but organic growth from existing facilities has inherent limits when capacity expansion is restricted.

6. Canadian Dollar / US Dollar FX Exposure

MFC earns in US dollars and reports in US dollars, but is listed on the TSX and pays dividends in Canadian dollars. Dividend declarations require a CAD/USD conversion. When the Canadian dollar strengthens, the CAD value of US hospital earnings contracts, which can pressure the dividend or require management to accept a lower CAD dividend at the same USD payout. This is a structural risk embedded in the company's Canadian listing for a US-operating business.

9. Walk the Talk

Concalls used: Q2 2025 (August 7, 2025), Q3 2025 (November 6, 2025), Q4 2025 (March 12, 2026), Q1 2026 (May 7, 2026). Q1 2026 was reported sixteen days ago, comfortably within the 90-day recency requirement.

Q2 2025: The Challenging Quarter and the Commitments Made

Q2 2025 was the most difficult call in the series. Revenue came in below expectations, Sioux Falls posted a material volume disruption, and Arkansas was dealing with pain management physician departures. The stock dropped nearly 6% in pre-market trading following the announcement.

CEO Jason Redman's response was measured and specific. On Sioux Falls:

"We look forward to Sioux Falls' return to more normalized operations in the back half of the year."

This was a testable commitment: the disruption was described as logistical (a physician group clinic relocation, not a physician departure), and management presented it as temporary. On Arkansas, management disclosed two specific recruitment actions: a new pain doctor starting immediately and a new spine surgeon starting in September 2025. CFO Watson also addressed regulatory risk directly, stating that Medicaid is immaterial to revenue and that site neutrality changes are not expected before 2027-2028. This was concrete guidance that would either age well or poorly.

Q3 2025: Sioux Falls Delivered, Pain Management Still Lagging

Q3 2025 delivered on the Sioux Falls commitment. Overall revenue from continuing operations rose meaningfully year-over-year. The Q3 concall specifically cited Sioux Falls Specialty Hospital's recovery following the referral group's clinic relocation, confirming the logistical disruption had resolved as management predicted. The Sioux Falls promise was kept.

The Arkansas recruitment was partially delivered. The spine surgeon started in September as announced, and surgical case volumes showed improvement at the facility level. However, pain management cases still declined more than 15% in Q3. The new pain doctor had started but had not yet built sufficient volume to offset the departures. Management noted continued recruitment efforts but set no specific recovery timeline.

One notable feature of the Q3 2025 call: there were no analyst questions. Management delivered prepared remarks on strong results, announced the completed CIBC credit facility, mentioned ongoing physician recruitment, and closed the call. The absence of Q&A meant no external scrutiny of the pain management trajectory.

**Q4 2025: Strong Results, Persistent Pain Management Headwind, New Q4 2025: Strong Results, Persistent Pain Management Headwind, New Capital

Q4 2025 was the strongest quarter in the series. Revenue from continuing operations grew 6.9%, operating income jumped more than 20%, and adjusted EBITDA rose 12%. The full year 2025 produced the company's strongest capital return effort in its history. Management also announced the Oklahoma Spine Hospital sale for January 2026 closing at US$46 million - delivering on the divestiture strategy that had been telegraphed since the September 2022 pivot.

"Our focus on optimizing operations and enhancing service offerings has driven these strong financial results." - CEO Jason Redman, Q4 2025 concall

However, pain management cases at Arkansas continued declining - down more than 13% in Q4. This was the third consecutive quarter of decline since management first disclosed the issue and described specific recruitment steps. The pattern suggests either that the pain management physician market in Arkansas is tighter than management initially implied, or that new physicians require longer ramp periods. Management on the Q4 call did not provide a revised timeline for pain management recovery, nor did they set a specific capital deployment date for the OSH proceeds.

Q1 2026: Momentum Confirmed, Pain Still Unresolved

Q1 2026 was operationally strong: continuing operations revenue grew more than 10% year-over-year, driven by favorable payer mix and orthopedic/spine volume growth. Net income on a basic EPS basis jumped dramatically, boosted by the gain recognized on the Oklahoma Spine Hospital sale completed January 30, 2026. On an operating basis, EPS came in below analyst estimates of US$0.24.

Pain management cases declined more than 21% in Q1 2026 - the steepest decline yet and the fifth consecutive quarter of deterioration. More than a full year after management first announced targeted recruitment, the pain management service line has not stabilized. The pace of decline is actually accelerating.

The Q1 2026 call introduced a separate shareholder/analyst call format with prepared remarks. Management emphasized the strong payer mix, the cash position (consolidated cash of US$86.3 million with no corporate debt), and the evaluation of capital return alternatives.

Assessment

Management's credibility is bifurcated. On strategic commitments - the divestiture sequence, the capital return execution, the Sioux Falls recovery - they have been credible and delivered with reasonable precision. The Oklahoma Spine Hospital sale closed on the timeline disclosed. Sioux Falls recovered in H2 2025 as promised. The CIBC credit facility was completed on schedule. These are wins.

On the pain management physician recruitment at Arkansas, management has been consistently optimistic without delivering resolution. Four specific quarters of disclosed recruitment efforts have not reversed - and in the most recent quarter, accelerated - the volume decline. Management deserves credit for transparent disclosure of the issue from Q2 2025 onward. But the implicit promise that recruitment would resolve it within a quarter or two has not been kept. This is either a harder market than management realized, a longer ramp dynamic, or a deeper structural change in the pain management referral ecosystem at ASH.

Overall assessment: a management team that executes reliably on strategic capital decisions and delivers on logistical recovery situations like the Sioux Falls clinic relocation. Less reliable when promising physician-level operational recoveries, which depend on factors external to management's direct control.

10. Shareholder Friendliness Index

Dividends: MFC has maintained consecutive quarterly dividends for more than 22 years - a record spanning the 2008-2009 financial crisis, the COVID-19 pandemic, and the 2022 strategic pivot. The quarterly dividend was C$0.0805 per share through all of 2022 and 2023 (C$0.322 annually). It was raised to C$0.09 beginning Q2 2024 and has held at that level through Q1 2026 (C$0.36 annually) - a 12% increase representing the first dividend raise in several years. The company has paid dividends for 22+ consecutive years without a cut; the payout continues even through the divestiture and capital-return phase.

Buybacks and share count: MFC has been aggressive in a way that is genuinely unusual for a company of this size. In 2024, the Normal Course Issuer Bid (NCIB) retired approximately 1.7 million shares. In January through March 2025, MFC executed a Substantial Issuer Bid (SIB) acquiring approximately 3.4 million shares at C$18.00 per share, retiring approximately 14.7% of outstanding shares in a single transaction for C$60.7 million. Additional NCIB purchases through the remainder of 2025 brought total 2025 share retirement to approximately 5.2 million shares - eliminating roughly 22% of the share count in a single year. By Q1 2026, with an additional 318,400 shares repurchased under the NCIB, outstanding shares had fallen from approximately 22.9 million pre-SIB to roughly 18.9 million. The combined 2024-Q1 2026 share retirement has reduced the outstanding count by roughly 20% since year-end 2023. Per-share metrics have been structurally amplified by this activity.

Verdict: Returns Capital - aggressively. MFC eliminated 22% of its share count in 2025 alone through a combination of a substantial fixed-price tender and ongoing open-market buybacks, while simultaneously maintaining a 22-year dividend streak and raising the quarterly payment 12% in mid-2024. Capital return is not a secondary priority for this management team; it is the stated and executed strategy.

11. Insider Activities

Source: Insider transaction data for Medical Facilities Corporation (TSX: DR) is disclosed to SEDI (System for Electronic Disclosure by Insiders, sedi.ca). Transactions below are sourced from reports based on SEDI filings, as the SEDI search interface requires direct access and the data was confirmed via secondary aggregators citing the primary filings.

Recent Transactions (trailing 12 months)

(Source: SEDI filing, December 18, 2024, as reported across multiple secondary sources citing the primary filing)

No additional material insider transactions have been identified for the trailing 12-month period ending May 2026. The absence of observable transactions post-December 2024 through to May 2026 reflects the very low aggregate insider ownership - Simply Wall St data indicates Watson holds approximately 100 shares as of the most recent data, consistent with a near-complete liquidation of his direct position in December 2024.

Reading the Watson Sale

Watson sold 7,800 shares at an average price of C$16.31 on December 18, 2024. The critical context: this represented approximately 99% of his direct individual holding at the time of the trade. The reason is not disclosed in any filing or associated announcement.

Several explanations are plausible without specific disclosure. December timing is consistent with year-end portfolio rebalancing or tax-loss management. The absolute dollar amount (C$127,000) is modest for a CFO-level executive, suggesting this was likely driven by personal financial considerations rather than a calculated bearish signal about the business. No 10b5-1-equivalent pre-arranged trading plan was disclosed in the Canadian context.

However, the fact that Watson sold essentially his entire direct stake - rather than a portion - is notable. It is the behavior of a holder seeking to liquidate a position entirely, not one selectively trimming. Combined with the near-zero institutional building of the insider base (overall insider ownership at 0.00057% of outstanding shares), it reflects a management team that does not maintain meaningful personal economic alignment with the stock they administer.

No insider buying has been identified in the trailing 12 months from any director, officer, or significant shareholder.

Net Assessment

Insider activity is sparse, and the net signal is neutral-to-mildly negative. The only significant transaction in the review period is the CFO's sale of essentially his entire direct stake, for a relatively small absolute amount and without disclosed reason. There is no offsetting insider buying to indicate management conviction in near-term appreciation. Institutional ownership stands at approximately 9.3%, with general public (retail) ownership at roughly 90.7% - suggesting this is a largely retail-owned name with minimal institutional attention.

For a company that has been buying back shares aggressively at scale - implicitly asserting that those shares are undervalued - the complete absence of management personal purchases is a notable inconsistency. Shareholders could reasonably observe that the company finds the stock worth buying at the corporate level but not at the personal portfolio level.

Note: Comprehensive SEDI search for all insiders (directors beyond Watson, major shareholders) was attempted but full database access requires the SEDI portal's authenticated search. The summary above reflects what was identifiable via secondary sources citing SEDI filings. If additional transactions exist that were not surfaced by aggregator reports, they would be available directly via sedi.ca.

12. Scenarios

Bull Case

MFC's two-hospital platform becomes a fortress of compounding per-share value. Management deploys the consolidated cash position through a third Substantial Issuer Bid, retiring another 15-20% of remaining shares at current prices and bringing the outstanding count to roughly 15 million. The per-share earnings base amplifies immediately.

Meanwhile, the pain management physician recruitment at Arkansas finally delivers. New practitioners ramp their practices, case volumes stabilize by mid-2026, and ASH's revenue mix returns to prior composition. The spine surgical volumes, which have been recovering, continue growing as the September 2025 hire builds their referral base. Sioux Falls, already the dominant force in South Dakota surgical volume at 45% market share, continues growing procedures in line with demographics - 3-4% per year as the baby boomer cohort ages into peak orthopedic surgery years - without requiring additional capital investment.

CMS's progressive expansion of ASC-covered procedures sends more complex cases toward freestanding specialty hospitals. SFSH's Blue Distinction Center+ status channels Wellmark-insured patients preferentially. Arkansas Surgical Hospital's six consecutive Human Experience Guardian awards translate into measurable commercial contract advantages at the next renewal cycle.

The quarterly dividend is raised to C$0.10-0.12 as the per-share earnings base grows from volume improvement and share count reduction simultaneously. By year three of this scenario, MFC is a lean, unlevered two-hospital platform - ACA-protected from new direct competition - with a rising dividend, shrinking share count, and a fully normalized clinical operation.

Base Case

The two hospitals grow modestly. Pain management at Arkansas partially recovers by the end of 2026 as the new physician cohort ramps, but never fully returns to prior volume. Sioux Falls maintains its dominant market position and grows volume in line with South Dakota demographics at 2-3% annually. Combined continuing operations revenue grows in the low-to-mid single digits year-over-year.

MFC deploys the accumulated cash primarily through continued NCIB buybacks over the next two to three years, reducing the share count by another 10-15% cumulatively. The C$0.09 quarterly dividend is maintained without increase, as management is cautious about committing to a higher level until capital deployment is resolved. No major acquisition materializes: the company cannot find physician-owned specialty hospitals at the multiples implied by the Black Hills Surgical sale (approximately 9x EBITDA) or better, and the ACA restrictions mean there are no new competitors entering their existing markets either.

The outcome: a stable, self-contained business generating consistent cash flows from two quality hospitals, returning capital to a steadily shrinking pool of shareholders, operating behind a regulatory moat that has been in place since 2010 and shows no sign of lifting. Unremarkable but credible.

Bear Case

The pain management problem at Arkansas intensifies rather than resolves. A departure extends beyond pain management to include a high-volume orthopedic or spine surgeon - the revenue backbone of ASH. Because the hospital has 13 operating rooms and a specialized workforce, fixed costs cannot be reduced proportionally when volume falls. The impact on operating income per case volume lost is disproportionate.

Simultaneously, site neutrality regulatory action arrives earlier than the 2027-2028 CFO guidance implied. A specific legislative change reduces the reimbursement premium that physician-owned specialty hospitals receive from commercial insurers in contract renewal cycles. ASH and SFSH, which both rely on above-average commercial rates relative to CMS-set reimbursement, absorb margin compression over successive contract cycles.

Management, facing pressure to deploy the substantial cash position and restore investor confidence, pursues an acquisition of a physician-owned surgical hospital at a price that proves too high. The acquired facility underperforms its underwriting assumptions - a pattern that has tripped up specialty hospital acquirers before. The combination of declining revenue at existing hospitals, compressed margins from site neutrality, and capital misallocation in the acquisition compounds over 24-36 months.

In this scenario, MFC ends the period having consumed its cash reserves, facing structurally weaker revenue at its two core hospitals, and finally cutting the dividend after 22+ years of consecutive payments - a signal that resets investor expectations and forces a re-rating.

Sources:

• Earnings call transcript: Medical Facilities Q1 2026 revenue beats despite EPS miss
• Medical Facilities Corporation Q1 2026 First Quarter Results
• Earnings call transcript: Medical Facilities Q4 2025 earnings reflect solid growth
• Earnings call transcript: Medical Facilities Q3 2025 sees revenue rise 7.5%
• Earnings call transcript: Medical Facilities Q2 2025 results miss expectations
• Medical Facilities Corporation Reports Fourth Quarter and FY 2025 Results
• Medical Facilities Corporation Reports Fourth Quarter and FY 2024 Results
• Medical Facilities Corporation Announces Sale of Oklahoma Spine Hospital
• Medical Facilities Corporation Announces Substantial Issuer Bid for up to $80,750,000
• Medical Facilities Corporation Announces Results of Substantial Issuer Bid
• Sioux Falls Specialty Hospital
• Medical Facilities Corporation - Overview and Milestones
• Medical Facilities Corporation - Investor Information
• Arkansas Surgical Hospital - Physician Owners
• Medically Facilitated Value Creation - Neglected Value Chronicles
• Medical Facilities Corporation Dividend History
• Insider Selling: Medical Facilities Co. CFO Sells 7,800 Shares
• CMS CY 2026 OPPS and ASC Final Rule
• Ambulatory Surgery Center Market Size & Future Scope
• Medical Facilities Corporation - Sale of Black Hills Surgical Hospital